Cipla Limited

NSE: CIPLA

Pharma Pharmaceuticals

₹1,422

-0.64%EOD · 19 Aug

Mumbai-based generics company known for humanitarian pricing — first to offer antiretroviral HIV drugs at 1% of Western cost. Strong in respiratory, anti-infectives, and oncology.

Market Cap

₹1.15 L Cr

52W Range

₹1673 / ₹1166

Volume

434K

54.5% delivery

1Y Return

-7.8%

P/E Ratio

34.8

P/B Ratio

3.4

ROE

11.7%

Debt / Equity

1.78

Peers in Pharma

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Cipla Limited(this stock)	₹1,422	₹1.15 L Cr	34.8	3.4	11.7%	0.89%
Sun Pharmaceutical Industries LimitedSUNPHARMA	₹1,900	₹4.56 L Cr	38.3	5.5	14.7%	0.83%
Lupin LimitedLUPIN	₹2,225	₹1.02 L Cr	18.5	4.5	26.9%	0.80%
Dr. Reddy's Laboratories LimitedDRREDDY	₹1,170	₹97,461 Cr	30.2	2.6	8.8%	0.66%

Technical Indicators

Full analysis · objective math, not advice

Returns

-0.6%

-2.5%

+0.8%

+1.5%

+10.9%

-7.8%

Weinstein Stage

Stage 1 — Basing (accumulation)

RSI (14)

23 Oversold

Trend Template

2/7weak

RS vs Nifty (3M)

+0.4pp

Moving Averages (price vs MA)

20-DMA

₹1458

below

50-DMA

₹1445

below

150-DMA

₹1366

above

200-DMA

₹1384

above

From 52W High

-15.0%

From 52W Low

+22.0%

Support (20D)

₹1415

Resistance (20D)

₹1491

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+5.9% CAGR

Up 7 of last 11 years

Earnings Quality

Mostly cash-backed

OCF / Net Profit = 0.81x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.